Status:

RECRUITING

Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation

Lead Sponsor:

Baystate Medical Center

Conditions:

Opioid Use Disorder

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The increasing morbidity and mortality of the opioid epidemic has necessitated a reevaluation of current addiction treatment paradigms: medications for opioid use disorder, such as buprenorphine and m...

Detailed Description

Participants (ED patients with untreated opioid use disorder) will be enrolled and followed prospectively before and after an ED-wide intervention training clinicians to use "Talk About It," a paper-b...

Eligibility Criteria

Inclusion

  • Patients aged 16 and older
  • presenting with indications for Medications for Opioid Use Disorder (MOUD) initiation (opioid overdose, opioid withdrawal, complications of injection opioid use, untreated OUD)
  • not currently on buprenorphine or methadone (in the past 7 days).
  • (Buprenorphine is FDA approved for patients aged 16 and older, so 16- and 17-year-olds may be included with parental consent.)

Exclusion

  • No Opioid Use Disorder (OUD)
  • already on MOUD

Key Trial Info

Start Date :

June 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2026

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT06527820

Start Date

June 1 2024

End Date

August 30 2026

Last Update

July 31 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Baystate Medical Center

Springfield, Massachusetts, United States, 01199